Department of Emergency, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6596-6601. doi: 10.26355/eurrev_201908_18547.
Growing evidence in recent years have demonstrated that the dysregulation of microRNAs (miRNAs) strongly affected the biological development and progression of human tumors, including glioma. There have been few studies on the clinical significance of miRNAs in glioma. The aim of our study is to explore the expression pattern and the value of miR-3653 in the prognosis of glioma patients.
qRT-PCR assays were performed to the miR-3653 expression level in 168 cases of glioma tissues and matched normal tissues. The correlations of miR-3653 expression level with the clinicopathological factors in glioma patients were analyzed. The associations between miR-3653 expression and survival of glioma patients were investigated by the Kaplan-Meier analysis and the log-rank test. The prognostic value of miR-3653 was estimated via univariate and multivariate analysis.
We presented that miR-3653 level in glioma tissues is notably reduced compared to matched non-cancerous brain tissues (p<0.01). Clinical research revealed that the lower miR-3653 expression was associated with larger tumor size and lymph node metastasis, lower KPS (p=0.028), and advanced WHO grade (p=0.019). Moreover, the clinical data further suggested that the low expression of miR-3653 predicted a worse 5-year overall survival in glioma patients. Finally, the multivariate analysis confirmed that low miR-3653 expression (HR=2.682, 95% CI: 1.148-4.281, p=0.021) was a significant independent predictor of poor survival in glioma.
Our findings suggested that miR-3653 could serve as a valuable prognostic indicator in glioma. Further researches are required to explore the potential function and mechanism of miR-3653 in glioma.
近年来越来越多的证据表明，microRNAs（miRNAs）的失调强烈影响了人类肿瘤的生物学发展和进展，包括脑胶质瘤。miRNAs 在脑胶质瘤中的临床意义研究较少。本研究旨在探讨 miR-3653 在脑胶质瘤患者预后中的表达模式和价值。
采用 qRT-PCR 法检测 168 例脑胶质瘤组织及配对正常组织中 miR-3653 的表达水平。分析 miR-3653 表达水平与脑胶质瘤患者临床病理因素的相关性。采用 Kaplan-Meier 分析和对数秩检验探讨 miR-3653 表达与脑胶质瘤患者生存的关系。采用单因素和多因素分析评估 miR-3653 的预后价值。
我们发现脑胶质瘤组织中 miR-3653 水平明显低于配对的非癌性脑组织（p<0.01）。临床研究表明，较低的 miR-3653 表达与较大的肿瘤大小和淋巴结转移、较低的 KPS（p=0.028）和较高的 WHO 分级（p=0.019）相关。此外，临床资料进一步表明，miR-3653 低表达预示脑胶质瘤患者 5 年总生存率较差。最后，多因素分析证实 miR-3653 低表达（HR=2.682，95%CI：1.148-4.281，p=0.021）是脑胶质瘤患者预后不良的独立预测因素。
本研究结果表明，miR-3653 可作为脑胶质瘤有价值的预后指标。需要进一步研究探讨 miR-3653 在脑胶质瘤中的潜在功能和机制。
